Recordati : Consolidated Financial Statements 2021 and related Report of the Auditing Firm

RECORDATI INDUSTRIA CHIMICA E FARMACEUTICA S.P.A.

Company under the management and coordination of Rossini Luxembourg S.àr.l. Registered office: Via Matteo Civitali, 1 ‐ Milan, Italy

Share capital: € 26,140,644.50 fully paid‐in

Tax identification code and registration number in the Milan Business Register: 00748210150 The Company prepares the consolidated financial statements for the Recordati group.

BOARD OF DIRECTORS

CONTROL, RISK AND CSR COMMITTEE

ANDREA RECORDATI

MICHAELA CASTELLI

Chairman

Chair

GUIDO GUIDI

Vice Chairman

SILVIA CANDINI PIERGIORGIO PELUSO

ROBERT KOREMANS

Chief Executive Officer

SILVIA CANDINI MICHAELA CASTELLI

Independent Lead Independent Director

REMUNERATION AND NOMINATIONS COMMITTEE

JOANNA LE COUILLIARD

Chair

GIORGIO DE PALMA JOANNA LE COUILLIARD GIAMPIERO MAZZA PIERGIORGIO PELUSO CATHRIN PETTY FRITZ SQUINDO

Independent

SILVIA CANDINI MICHAELA CASTELLI

Independent

BOARD OF STATUTORY AUDITORS

Group General Manager

ANTONIO SANTI

Chair

KIM STRATTON

LIVIA AMIDANI ALIBERTI EZIO SIMONELLI

Statutory Auditors

ANDREA BALELLI

PATRIZIA PALEOLOGO ORIUNDI

Alternate Auditors

AUDIT FIRM

EY S.p.A.

The 2021 consolidated financial statements are presented in accordance with the International Financial Reporting Standards (IFRSs) issued or revised by the International Accounting Standards Board (IASB) and endorsed by the European Union, as well as the provisions issued implementing Art. 9 of Italian Legislative Decree 38/2005. The same accounting standards were used in the preparation of the 2020 consolidated financial statements.

This document contains forward‐looking statements relating to future events and future operating, economic and financial results of the Recordati group. By their nature, forward‐looking statements involve risk and uncertainty because they depend on the occurrence of future events and circumstances. Actual results may therefore differ materially from those forecast as a result of a variety of reasons, most of which are beyond the Recordati group's control. The information on the pharmaceutical specialties and other products of the Recordati group contained in this document is intended solely as information on the Recordati group's activities and therefore, as such, it is not intended as medical scientific indication or recommendation, nor as advertising.

This document in PDF format does not meet the obligation arising from the ESEF Regulation.

Recordati, an international group

REVENUE

1,580.1

Million Euros

NET INCOME

386.0

Million Euros

EMPLOYEES

Exceed

4,300

4

RECORDATI, AN INTERNATIONAL GROUP

Recordati is a well‐established international pharmaceutical group listed on the Italian Stock Exchange since 1984. The Recordati group is based in Milan and is one of Italy's oldest pharmaceutical companies.

Since it was founded in 1926, Recordati has grown consistently thanks to the success of its products and its growth and development strategy based on internationalisation and diversification, also implemented through an ongoing acquisition strategy initiated in the 1990s. The Group is committed to seeking new opportunities and faces the challenges of a constantly changing marketplace with determination. In 2021, revenue of € 1,580.1 million was generated with a staff of 4,303 employees.

A number of branches are currently operational in Europe and globally. In addition to it subsidiaries in Western and Central and Eastern European countries, the Group has a direct presence in Turkey, North Africa, the U.S.A., Canada, Mexico, in some South American countries, the Middle East, Japan and Australia. Recordati also sells its products in about 150 markets through license agreements. Alongside its geographic expansion, the Group has developed a significant and increasing global presence in the pharmaceutical segment for the treatment of rare diseases. In addition, the Group constantly enhances its treatment offering by developing new products and forming alliances with research institutes and other pharmaceutical companies.

The Group's most important Specialty and Primary Care products include those in the cardiovascular area, with lercanidipine, a latest‐generation calcium channel blocker indicated for the treatment of hypertension, discovered and developed entirely at the Recordati research laboratories, and its combination with enalapril, a widely prescribed ACE inhibitor. The Group's presence in this treatment area also includes the well‐established metoprolol‐based products, a beta‐blocker mainly indicated to control a range of conditions including hypertension, angina pectoris, cardiac rhythm disorders, maintenance treatment after a myocardial infarction, and functional heart disorders with palpitations.

In addition to the cardiovascular segment, the Group's product portfolio covers a range of different treatment areas. More specifically, over the years, Recordati has acquired specific and wide‐ranging know‐how in the urogenital area, with well‐recognized drugs for the treatment of benign prostatic hyperplasia such as silodosin, and of urinary incontinence, such as flavoxate. The offer has been recently expanded to include a leuprorelin acetate depot formulation for subcutaneous injection indicated for palliative care in hormone‐dependent prostate cancer (PCa). In the metabolic area, pitavastatin, a latest‐generation statin for controlling hypercholesterolemia, is also marketed in a number of countries and in the central nervous system area, an innovative anti‐psychotic drug for the treatment of schizophrenia, cariprazine, a new and effective treatment for this seriously debilitating mental disorder.

Recordati develops, produces and markets drugs for the treatment of rare diseases through Recordati Rare Diseases, a group of companies operating globally and dedicated entirely to serve patients suffering from these diseases. Historically focused on rare genetic metabolic illnesses. This business segment was recently consolidated with the addition of new products to its portfolio and with the acquisition of additional important products in the area of rare endocrinology diseases.

Recordati has six pharmaceutical production facilities and a packaging and distribution facility dedicated to rare disease products, all of which operate in full compliance with environmental protection regulations and current Good Manufacturing Practice (cGMP). Recordati also produces a number of active ingredients and intermediates for the pharmaceutical industry at two pharmaceutical chemical plants: one in Campoverde di Aprilia, Italy, and the other in Cork, Ireland.

5